Impax Small Cap Investor holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Impax Small Cap Fund Investor Class PXSCX
- NAV / 1-Day Return 21.33 / +0.61 %
- Total Assets 891.1M
-
Adj. Expense Ratio
1.160%
- Expense Ratio 1.160%
- Distribution Fee Level Average
- Share Class Type No Load
- Category Small Blend
- Investment Style Small Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.00
- Turnover 36%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 12:11 AM GMT+0
Morningstar’s Analysis PXSCX
Will PXSCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 31.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Victory Capital Holdings Inc Class A | 4.96 | 47M | Financial Services |
JPMorgan US Treasury Plus MMkt IM | 4.77 | 45M | Cash and Equivalents |
Crinetics Pharmaceuticals Inc | 3.88 | 37M | Healthcare |
Pinnacle Financial Partners Inc | 3.47 | 33M | Financial Services |
Agree Realty Corp | 3.04 | 29M | Real Estate |
Acadian Asset Management Inc | 2.97 | 28M | Financial Services |
Eastern Bankshares Inc Ordinary Shares | 2.94 | 28M | Financial Services |
SI-BONE Inc | 2.85 | 27M | Healthcare |
Neurocrine Biosciences Inc | 2.59 | 25M | Healthcare |
Ligand Pharmaceuticals Inc | 2.24 | 21M | Healthcare |